Lineage Cell Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Lineage Cell Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Lineage Cell Therapeutics: 5 sponsored US clinical trials, 1 recruiting.
Lineage Cell Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Spinal Cord Injuries, with 2 trials.
Upper-quartile sponsor footprint
Lineage Cell Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury
NCT06841770
LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1
NCT05975424
LTFU Study of Subjects Who Received GRNOPC1
NCT05919563
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
NCT02302157
Safety Study of GRNOPC1 in Spinal Cord Injury
NCT01217008
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
What is open in the Lineage Cell Therapeutics pipeline
1 recruiting of 5 indexed (20% open); 2 completed (40%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Spinal Cord Injuries (2 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lineage Cell Therapeutics: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Lineage Cell Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Lineage Cell Therapeutics page
5 registered trials is a research-attention snapshot, not an endorsement of Lineage Cell Therapeutics or any single study.
- 1 of Lineage Cell Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Spinal Cord Injuries is the condition Lineage Cell Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Spinal Cord Injuries trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Lineage Cell Therapeutics pipeline card: 5 registered trials from official public datasets.Report a data error.